31.12.2023, 3113 Zeichen

Valneva: Valneva SE, a specialty vaccine company, today announced that the Company is modifying its financial guidance for 2023. Product sales guidance remains unchanged, as do anticipated R&D expenses. The €90 million to €110 million of other income related to proceeds from potential sale of the Company’s priority review voucher (PRV), which was previously expected before year-end, is now expected in early 2024.The Company’s previous guidance included expected total revenues and other income between €220 million and €260 million. The modified 2023 guidance now includes the previously stated product sales revenue of €130 million to €150 million, which the Company remains on track to achieve, as well as R&D expenses between €60 million and €70 million, which were recently reduced, primarily driven by lower than anticipated costs related to the closeout of the Company’s COVID-19 activities. Peter Bühler, Chief Financial Officer of Valneva, said, “We remain confident in our ability to sell our priority review voucher successfully at a price within the previously suggested range. As we continue to work actively toward a potential sale agreement, we look forward to providing an update in the new year.” The Company was awarded a tropical disease PRV in November 2023[ following U.S. FDA approval of IXCHIQ®, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. With this approval, IXCHIQ® became the world’s first licensed chikungunya vaccine available to address this unmet medical need. Valneva expects to launch the vaccine in the U.S. in early 2024. The Company has also drawn down the remaining $50 million made available under its debt financing agreement with funds managed by U.S. investment firms Deerfield Management Company and OrbiMed.
Valneva: weekly performance: 3.69%

Vienna Stock Exchange: High interest rates, persistent inflation and geopolitical tensions left their mark on the European stock markets in 2023. While the unfavourable conditions weighed on trading activity, the Vienna Stock Exchange registered a record year for bond listings. With Austriacard Holdinge and EuroTeleSites AG there were two new entries in the top segment prime market. The direct market plus for SMEs also grew with the listing of RWT AG. In addition, four companies – Wolford AG, BKS Bank AG, Lenzing AG and Kapsch TrafficCom AG – undertook a capital increase to raise equity. With a record year, the Vienna MTF strengthened its leading role among the exchange-regulated markets in Europe. In 2023, over 8,000 new bonds were issued on the Vienna Stock Exchange, significantly more than the previous record of 7,082 in 2021. In addition, the Vienna ESG segment for sustainable bonds exceeded the mark of 100 listings for the first time. The Vienna Stock Exchange serves a total of 900 active bond issuers from 37 countries.
ATX: weekly performance: 0.80%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (29/12/2023)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #794: ATX rauf, Pierer Mobility & Marinomed, Pierer-Bonds vs. Aktien, OMV & Stefan Zapotocky, Live Blick Change

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, S Immo, Porr, Immofinanz, CA Immo, EuroTeleSites AG, Frequentis, Erste Group, VIG, Andritz, EVN, Mayr-Melnhof, Cleen Energy, FACC, Hutter & Schrantz Stahlbau, Kapsch TrafficCom, Marinomed Biotech, Polytec Group, SW Umwelttechnik, UBM, Warimpex, Semperit, Oberbank AG Stamm, Agrana, Amag, Flughafen Wien, OMV, Palfinger, Österreichische Post, Telekom Austria, Uniqa.

---